Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Embolism

Launched by ESTER ASHRAF FARIED BESHAY · Oct 7, 2023

Keywords

ClinConnect Summary

This clinical trial is focused on understanding a condition called Chronic Thromboembolic Pulmonary Hypertension (CTEPH), which can develop after a serious lung blood clot known as a pulmonary embolism. The goal is to find out how common CTEPH is among patients who have had a pulmonary embolism and are still experiencing symptoms. The study will examine specific heart function measurements through tests, like echocardiograms, to see if they can help predict who might develop CTEPH after their initial clot.

To be eligible for this study, participants should be between 18 and 80 years old and have been diagnosed with an acute pulmonary embolism that falls into a certain severity category. However, those with other causes of high blood pressure in the lungs, severe kidney problems, or liver issues, or who cannot take blood thinners will not be able to participate. If you join the study, you can expect to undergo heart function tests and help researchers learn more about this serious condition, which could improve future care for patients like you.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Any patient diagnosed as acute pulmonary embolism ,aged between 18-80 years old which Pulmonary Embolism Severity Index (PESI) class III-V or sPESI ≥1,
• Exclusion Criteria:
• • Secondary causes for pulmonary hypertension Severe kidney injury(eGFR\>30 mg/dl/1.7m2) Hepatic affection Contraindication to anti-coagulation